PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Trial results reveal first targeted treatment to boost survival for esophageal cancer

2014-11-05
(Press-News.org) PATIENTS with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).

Up to one in six patients with oesophageal cancer were found to have EGFR duplication in their tumour cells and taking the drug gefitinib, which targets this fault, boosted their survival by up to six months, and sometimes beyond.

This is the first treatment for advanced oesophageal cancer shown to improve survival in patients whose initial course of chemotherapy treatment has failed. It is also the first time a targeted treatment of any kind has proved effective in this disease, although chemotherapy and some targeted drugs have shown benefit in the second line treatment of other cancers of the digestive system including stomach cancer.

The trial – called 'TRANS-COG' – looked for extra copies of a gene called EGFR in tumour samples from 295 deceased oesophageal cancer patients who had received either gefitinib or placebo as part of the COG trial.

Of the 48 patients who had extra EGFR copies in their tumour cells, 13 per cent of those who had gefitinib survived for at least a year, while none of the patients who received a placebo survived that long.

Giving gefitinib to patients who didn't have extra EGFR copies made no difference to how long they survived. This suggests that EGFR testing could identify a subgroup of oesophageal patients who may benefit from gefitinib.

Dr Russell Petty, a medical oncologist from the University of Aberdeen, who is presenting the data, said: "This is exciting news in our field. It's the first time any drug has shown survival benefit for oesophageal patients who have stopped responding to their initial treatment. To date there's been disappointingly little progress in treating this cancer type, which kills nearly 8,000 people a year and sadly is often diagnosed late making it difficult to treat successfully.

"It's thought that up to 16 per cent of oesophageal cancer patients could benefit from gefitinib, providing valuable extra months of life to people who would otherwise have had very few options available to them."

Irene Black's late husband, Roy, was diagnosed with oesophageal cancer in January 2011 aged 78, after having problems swallowing and later being rushed into A&E for an emergency endoscopy. He was given an intense course of chemotherapy and radiotherapy at Aberdeen Royal Infirmary, but unfortunately the cancer stopped responding and the family were told it was incurable. It was then that Roy decided to join the trial.

Irene said: "There is no doubt in my mind that, if it wasn't for the trial, Roy wouldn't have been with us for so long. He managed to get back to his bingo, which he loved, surrounded by friends and we booked a four night holiday on the west coast at Fort William. I will always treasure that holiday - if it wasn't for the trial we may not have had the special time together at the end.

"It's comforting to know that the trial Roy took part in when he was alive may help patients with this devastating type of cancer live longer in the future."

Professor Matt Seymour, NCRI's clinical research director said: "Although the survival benefit for these patients was relatively modest, this trial is an important step forwards for a type of cancer where progress in treatment has fallen behind other cancers in recent decades. While there has been some success in treating other cancers of the digestive system, oesophageal cancer remains extremely difficult to treat, with only 13 per cent of patients surviving five years or more.

"It will be interesting to see whether this drug, if properly targeted at the right patients, could offer similar benefits to those with earlier stage disease and also whether other drugs that target EGFR could prove to be even more effective."

INFORMATION:

The TRANS-COG trial was funded by the Scottish Government's Chief Scientist Office, the Cameron Clinical Academic Fellowship and the Grampian Gastro-oesophageal Cancer Research Fund (GASTROCAN).



ELSE PRESS RELEASES FROM THIS DATE:

Researchers engineer a 'smart bomb' to attack childhood leukemia

Researchers engineer a smart bomb to attack childhood leukemia
2014-11-05
Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer — called B-lineage acute lymphoblastic leukemia (ALL). In a November study in the new peer-reviewed, open-access journal EBioMedicine, they describe how this approach could eventually prove lifesaving for children who have relapsed after initial chemotherapy and face a less than 20 percent chance of long-term survival. "We knew that we could kill chemotherapy-resistant leukemia cells ...

How important is long-distance travel in the spread of epidemics?

How important is long-distance travel in the spread of epidemics?
2014-11-05
The current Ebola outbreak shows how quickly diseases can spread with global jet travel. Yet, knowing how to predict the spread of these epidemics is still uncertain, because the complicated models used are not fully understood, says a University of California, Berkeley biophysicist. Using a very simple model of disease spread, Oskar Hallatschek, assistant professor of physics, proved that one common assumption is actually wrong. Most models have taken for granted that if disease vectors, such as humans, have any chance of "jumping" outside the initial outbreak area ...

Study shows benefits of being fat (but not too fat) for deep-diving elephant seals

Study shows benefits of being fat (but not too fat) for deep-diving elephant seals
2014-11-05
Researchers using a new type of tracking device on female elephant seals have discovered that adding body fat helps the seals dive more efficiently by changing their buoyancy. The study, published November 5 in the Proceedings of the Royal Society B, looked at the swimming efficiency of elephant seals during their feeding dives and how that changed in the course of months-long migrations at sea as the seals put on more fat. The results showed that when elephant seals are neutrally buoyant--meaning they don't float up or sink down in the water--they spend less energy ...

Oregon research team scores with 'The Concussion Playbook'

Oregon research team scores with The Concussion Playbook
2014-11-05
A University of Oregon researcher wants those "R" words to resonate among young athletes. They are key terms used in an online educational tool designed to teach coaches, educators, teens and parents about concussions. Brain 101: The Concussion Playbook successfully increased knowledge and attitudes related to brain injuries among students and parents in a study that compared its use in 12 high schools with the usual care practices of 13 other high schools during the fall 2011 sports season. The findings are online ahead of print in the Journal of Adolescent Health. Participants, ...

Blocking mitochondrial fission: An effective treatment for Parkinson's disease?

2014-11-05
A study led by a researcher from Plymouth University in the UK, has discovered that the inhibition of a particular mitochondrial fission protein could hold the key to potential treatment for Parkinson's Disease (PD). The findings of the research are published today, 5th November 2014, in Nature Communications. PD is a progressive neurological condition that affects movement. At present there is no cure and little understanding of why some people get the condition. In the UK one on 500 people, around 127,000, have PD. The debilitating movement symptoms of the disease ...

Cost and effect: Cheaper remedies should rule for diabetes nerve pain, U-M experts say

2014-11-05
ANN ARBOR, Mich. — Millions of people with diabetes take medicine to ease the shooting, burning nerve pain that their disease can cause. And new research suggests that no matter which medicine their doctor prescribes, they'll get relief. But some of those medicines cost nearly 10 times as much as others, apparently with no major differences in how well they ease pain, say a pair of University of Michigan Medical School experts in a new commentary in the Annals of Internal Medicine. That makes cost -- not effect -- a crucial factor in deciding which medicine ...

New dietary supplement beats calcium, vitamin D for bone strength

New dietary supplement beats calcium, vitamin D for bone strength
2014-11-05
TALLAHASSEE, Fla. — A new study by a Florida State University researcher reveals that a new dietary supplement is superior to calcium and vitamin D when it comes to bone health. Over 12 months, Bahram H. Arjmandi, Margaret A. Sitton Professor in the Department of Nutrition, Food and Exercise Sciences and Director of the Center for Advancing Exercise and Nutrition Research on Aging (CAENRA) at Florida State, studied the impact of the dietary supplement KoACT® versus calcium and vitamin D on bone loss. KoACT is a calcium-collagen chelate, a compound containing ...

Vanderbilt researchers explore links between grammar, rhythm

2014-11-05
A child's ability to distinguish musical rhythm is related to his or her capacity for understanding grammar, according to a recent study from a researcher at the Vanderbilt Kennedy Center. Reyna Gordon, Ph.D., a research fellow in the Department of Otolaryngology and at the Vanderbilt Kennedy Center, is the lead author of the study that was published online recently in the journal Developmental Science. She notes that the study is the first of its kind to show an association between musical rhythm and grammar. Though Gordon emphasizes that more research will be necessary ...

VTT develops a simple but extremely sensitive magnetometer

2014-11-05
VTT Technical Research Centre of Finland has developed an innovative magnetometer that can replace conventional technology in applications such as neuroimaging, mineral exploration and molecular diagnostics. Its manufacturing costs are between 70 and 80 per cent lower than those of traditional technology, and the device is not as sensitive to external magnetic fields as its predecessors. The design of the magnetometer also makes it easier to integrate into measuring systems. Magnetometers are sensors that measure magnetic fields or changes in magnetic fields. The kinetic ...

Could non-gluten proteins play a role in celiac disease?

2014-11-05
Although gluten-free foods are trendy among the health-conscious, they are necessary for those with celiac disease. But gluten, the primary trigger for health problems in these patients, may not be the only culprit. Scientists are reporting in ACS' Journal of Proteome Research that people with the disease also have reactions to non-gluten wheat proteins. The results could help scientists better understand how the disease works and could have implications for how to treat it. Armin Alaedini, Susan B. Altenbach and colleagues point out that celiac disease symptoms are triggered ...

LAST 30 PRESS RELEASES:

New discovery reveals the spinal cord’s role in bladder control

Kākāpō decline reveals threat of parasite coextinction

Astrocytes identified as hidden culprit behind PTSD

Offering self-collection kits in routine GP appointments could prevent 1,000 women a year from developing cervical cancer

European study offers clearer picture of childhood brain tumor survival

The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest

Tiny artificial cells can keep time, study finds

How aging quiets lupus and brings relief to some older patients

Research alert: Synergistic treatment approach supercharges cancer immunotherapy

White veteran high users of online portal generate and exchange more messages than certain patient minorities in the Veterans Health Administration

Web-based tool helps Michigan physicians navigate diabetes coverage and prior authorization

Most primary care patients with opioid use disorder who start treatment stay engaged

U.S.-born Latinos have higher rates of obesity compared to foreign-born Latino and white youth

Study finds veterans experiencing homelessness who gain housing are more likely to get colorectal and breast cancer screenings

Body fat percentage beats BMI in predicting 15-year mortality risk among U.S. adults ages 20 to 49

Umbrella review summarizes family physicians’ experiences with clinical integration

HEAL protocol addresses human trafficking in Brazilian primary care

Study finds uneven progress toward diabetes goals across patient groups in the enhanced primary care diabetes program

Veterans experiencing homelessness who secure housing more likely to get cancer health screenings

Family physicians improve rural maternity outcomes but those in high-need states need support

Tip sheet summaries Annals of Family Medicine July/August 2025

TFLN-based RGB multiplexer for energy-efficient laser beam scanning

On a Florida bombing range, endangered woodpeckers get a second chance

Study identifies gene clusters in rhizobia linked to robust legume growth

Remapping the evolutionary tree of butterflies

Employees who spot problems help the bottom line, so why do leaders give more power to bootlickers?

Could living near water mean you’ll live longer?

Alcohol withdrawal syndrome linked to worse surgical outcomes, higher costs

US POINTER trial: Structured lifestyle intervention delays cognitive decline

Detecting a potential behavioral biomarker for Parkinson’s disease in mice

[Press-News.org] Trial results reveal first targeted treatment to boost survival for esophageal cancer